Does Delaware Medicaid Cover Wegovy and Zepbound? Yes, With a Health-Condition Rule

Yes. As of November 2026, Delaware Medicaid covers Wegovy, Zepbound and Saxenda for weight loss with prior authorization, which puts it among the few states that pay for these drugs at all.^[1][2] The catch is that adults must also document a health problem tied to their weight, high blood pressure or sleep apnea for instance, even when the BMI is 30 or higher.^[1]

Does Delaware Medicaid cover Wegovy for weight loss?

It does, which sets Delaware apart. Under federal law, every state may leave weight-loss drugs out of Medicaid, and most do.^[5] Delaware chose the other path in 2019, when it wrote into its state plan that drugs for obesity would be covered “to address weight loss with co-morbid conditions with prior authorization.”^[3] Our explainer on how Medicaid handles Ozempic and Wegovy covers the federal background.

In 2026 the state rewrote that line. The amendment CMS approved on June 3, 2026, effective back to January 1, says the state will pay for the weight-loss drugs named on a list it posts online.^[2] CMS described the change as giving the state more flexibility over which drugs it covers for weight management.^[2] In practice the covered list can now change without another plan amendment, so the current state list is the document to check.

Who qualifies for Wegovy or Zepbound under Delaware Medicaid?

The most detailed criteria in print come from Delaware First Health’s policy, which names Saxenda, generic liraglutide, Wegovy and Zepbound as the anti-obesity drugs needing prior authorization.^[1] For adults, the request must show all of the following.^[1]

• A BMI above 30, or above 27 when a qualifying condition is present.^[1]
• At least one weight-related condition in every case. The policy says this matches the Delaware Medicaid state plan; the plan page approved in 2026 leaves the details to the state’s posted list.^[1][2]
• A reduced-calorie diet and more physical activity, unless a health problem rules exercise out.^[1]
• Use that matches the FDA label, and for a non-preferred drug, failed trials of two preferred ones first.^[1]

That second point is stricter than the labels. Wegovy and Zepbound are approved for adults with obesity alone, with a second condition needed only in the overweight range.^[6][7] Delaware asks for the condition at any BMI, and the policy dates that change to early 2026.^[1] The conditions that count are listed in a table in the policy.^[1]

The first approval lasts six months, filled 30 days at a time.^[1] Which drugs count as preferred is set by the state list, which we could not open. Ask the prescriber’s office or the plan which product to request first, because a non-preferred drug needs two failed preferred trials.^[1]

What does it take to stay on the drug in Delaware?

Renewal depends on results. An adult must have lost at least 5% of starting weight, and a teenager at least 4%; with that documented, the drug is renewed for up to six months at a time, in up to 90-day fills.^[1] The rule that follows is unusually firm. If total loss ever falls below that floor, or a person regains more than half of what was lost, the policy says the authorization may not be renewed for at least a year.^[1]

That makes the weight record at each visit matter. Plateaus and some regain are common on these drugs, so anyone close to the line should talk with the prescriber before the renewal date about what the chart will show.

Is there a separate route for heart disease or fatty liver?

Yes, and both were added in 2026.^[1] The heart route matches Wegovy’s label use for cutting heart attack and stroke risk, but the policy confines it to people with established heart disease and a BMI from 27 up to just under 30.^[1][6] Anyone at 30 or above goes through the weight-loss route, where heart disease already counts as a qualifying condition.^[1]

The MASH route has the opposite profile: no BMI minimum at all, but a hepatologist or gastroenterologist must prescribe or co-manage, and F2 to F3 fibrosis must be shown by biopsy or a noninvasive test such as FibroScan or MRI-based imaging.^[1] Wegovy’s MASH use rests on accelerated approval.^[6] Both routes give six months at a time, and renewal needs only the prescriber’s statement that the drug still helps.^[1] Our page on GLP-1s and MASH covers the trial behind that use.

Sleep apnea has no route of its own in the policy, even though Zepbound is approved for it.^[1][7] Moderate to severe apnea instead counts as one of the qualifying conditions for weight-loss coverage, so a person with sleep apnea and obesity usually meets both tests through that route.^[1]

Can teenagers get a GLP-1 through Delaware Medicaid?

Yes. The pediatric criteria ask for an age within the drug’s FDA-approved range and a BMI-for-age of the 95th percentile or higher, with no added condition required.^[1] Wegovy and Saxenda are both approved from age 12 for obesity, Saxenda only above 60 kg, while Zepbound’s weight use is for adults.^[6][7][8] Our review of GLP-1 drugs in teenagers sets out the evidence for that age group.

Do all Delaware Medicaid plans use the same rules?

Delaware Medicaid runs through three health plans: AmeriHealth Caritas, Delaware First Health and Highmark Health Options.^[4] The state’s own enrollment page says prescriptions are covered directly by Medicaid, not through the plans, which points to one set of drug rules for everyone.^[4] Delaware First Health’s policy describes its 2026 revisions as matching the state plan and the state drug list, which supports that reading.^[1] The other two plans did not publish comparable criteria that we could find, so confirm with the plan named on the card.

State employees are a different case. Their health plan is a separate program that set its own copay for weight-loss drugs in 2026.

How do you appeal a denial in Delaware?

Read the reason first. Most denials under these criteria come from a missing piece: no documented condition, no BMI on file, or a renewal weight below the 5% floor.^[1] The first two can often be fixed by resubmitting with the records.

The deadline depends on who sent the notice, and the notice states it. When a managed care plan denies a request, federal rules give 60 days from the notice to appeal to the plan, then at least 90 and at most 120 days after the plan’s decision to ask for a state fair hearing.^[9][10] When the state denies directly, federal rules allow no more than 90 days from the mailing date to request a hearing.^[11] Our guide to prior authorization and appeals explains what to put in the file, and the Delaware state page summarizes the Medicaid facts.

What if you don’t qualify?

Someone with obesity but no listed condition, or who lost coverage under the renewal rule, is left with cash prices. Manufacturer copay cards do not help, because Lilly’s card terms exclude anyone enrolled in Medicaid.^[12] In the figures we track, Novo Nordisk’s self-pay price for most Wegovy pen doses is $349 a month, and Lilly’s self-pay Zepbound runs from $299 at the starting dose to $449 at higher doses refilled on schedule.^[12][13] Read each program’s terms on government coverage before signing up, and compare them in our list of the cheapest ways to pay without insurance.